Quickly and easily access information about MS, as well as current material about Society programs and services.
- Multi-Media PSA Campaign
Public service ads available in varied formats for print or broadcast media.
News
Jimmie Heuga: Remembering a Pioneer in Sports & Life
Feb 09, 2010
The National MS Society is deeply saddened at the passing of Jimmie Heuga, founder of The Heuga Center for Multiple Sclerosis, now Can Do MS, and 1964 bronze medalist in slalom at the Winter Olympics in Innsbruck, Austria.
Update on Tysabri and PML: UPDATED FEBRUARY 5
Feb 05, 2010
According to information released by Biogen Idec, as of January 12, 2010, there have been 31 confirmed cases of PML among people who have used Tysabri after it became available for prescription in July 2006. Some details about 24 of the cases are provided here.
Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
Jan 19, 2010
Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA
Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
2009: Substantial Progress Propelled MS Research Forward
Dec 15, 2009
This year saw exciting research progress, with unprecedented opportunities on the horizon and more scientists than ever working on important questions. While the economic environment resulted in an unfortunate slowing of funding, creating gaps in planned expenditures to support MS research, we hope this impact will be of short duration. Despite these challenges, the National MS Society continues to propel research forward and move us closer to a world free of MS.
Sponsor Receives “Refuse to File” Letter from the FDA for its Application Seeking Approval for Oral Cladribine -- Usually means agency deems application incomplete
Nov 30, 2009
EMD Serono announced that it has received a “refuse to file” letter from the U.S. Food and Drug Administration for the application it submitted in late September requesting approval of cladribine tablets for the treatment of relapsing MS. According to a company press release, the sponsor plans to request a meeting with the FDA to determine what would be required for the application to be accepted for review.